Emerging oligonucleotide therapeutics for rare neuromuscular diseases
Research and drug development concerning rare diseases are at the cutting edge of scientific technology. To date, over 7,000 rare diseases have been identified. Despite their individual rarity, 1 in 10 individuals worldwide is affected by a rare condition. For the majority of these diseases, there i...
Egile Nagusiak: | Aoki, Y, Wood, MJA |
---|---|
Formatua: | Journal article |
Hizkuntza: | English |
Argitaratua: |
IOS Press
2021
|
Antzeko izenburuak
-
Oligonucleotide-based therapies for neuromuscular disease
nork: Douglas, A, et al.
Argitaratua: (2015) -
Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
nork: Tsoumpra, MK, et al.
Argitaratua: (2019) -
Advances in oligonucleotide drug delivery
nork: Roberts, TC, et al.
Argitaratua: (2020) -
Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
nork: Ashok Verma
Argitaratua: (2018-01-01) -
Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
nork: Gait, M, et al.
Argitaratua: (2018)